Paraoxonase activity might be predictive of the severity of aortic valve stenosis

Journal of Heart Valve Disease

Volumn 19, Issue 4, 2010, Pages 453-458

  Cagirci, Goksel ^a   Cay, Serkan ^b   Karakurt, Ozlem ^a   Durmaz, Tahir ^c   Yazihan, Nuray ^d   Canga, Aytun ^b   Aydin, Cengiz ^e   Acikel, Sadik ^a   Kilic, Harun ^a   Topaloglu, Serkan ^b   Aras, Dursun ^b   Demir, Ahmet Duran ^b   Akdemir, Ramazan ^a  

^a MINISTRY OF HEALTH   (Turkey)

^b Yuksek Ihtisas Heart Education and Research Hospital   (Turkey)

^c ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^d ANKARA UNIVERSITY   (Turkey)

^e Biochemistry Department   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKER; PON1 PROTEIN, HUMAN;

ADULT; AGED; AORTA VALVE STENOSIS; ARTICLE; CALCIFICATION; CORRELATION ANALYSIS; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; ANGIOCARDIOGRAPHY; BLOOD; CALCINOSIS; COMPARATIVE STUDY; DOPPLER ECHOCARDIOGRAPHY; DOWN REGULATION; ECHOGRAPHY; ENZYMOLOGY; MIDDLE AGED; PREDICTIVE VALUE; PROGNOSIS; RADIOGRAPHY; SEVERITY OF ILLNESS INDEX; SPECTROPHOTOMETRY; TURKEY;

AGED; AORTIC VALVE STENOSIS; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; CALCINOSIS; CORONARY ANGIOGRAPHY; DOWN-REGULATION; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SPECTROPHOTOMETRY; TURKEY;

EID: 77956018766     PISSN: 09668519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Lindroos M, Kupari M, Heikkila J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: An echocardiographic study of a random population sample. J Am Coll Cardiol 1993;21:1220-1225
2. Olsson M, Dalsgaard CJ, Haegerstrand A, Rosenqvist M, Ryden L, Nilsson J. Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. J Am Coll Cardiol 1994;23:1162-1170
3. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the early lesion of 'degenerative' valvular aortic stenosis: Histological and immunohistochemical studies. Circulation 1994;90:844-853
4. O'Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, Otto CM. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol 1996;16:523-532
5. Olsson M, Thyberg J, Nilsson J. Presence of oxidized low-density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 1999;19:1218-1222
6. Ghaisas NK, Foley JB, O'Briain DS, Crean P, Kelleher D, Walsh M. Adhesion molecules in non-rheumatic aortic valve disease: Endothelial expression, serum levels and effects of valve replacement. J Am Coll Cardiol 2000;36:2257-2262
7. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: Pathogenesis, disease progression, and treatment strategies. Circulation 2005;111:3316-3326
8. Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular health study. J Am Coll Cardiol 1997;29:630-634
9. Otto CM, Lind BK, Kitzman DW, et al. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999;341:142-147
10. Barter PJ, Nicholls S, Rye A et al, Antiinflammatory properties of HDL. Circ Res 2004;95:764-772
11. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low density lipoprotein. FEBS Lett 1991;286:152-154
12. Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease. J Am Coll Cardiol 2006;48:e1-e148
13. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983;35:1126-1138
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
15. Palta S, Pai AM, Gill KS, et al. New insights into the progression of aortic stenosis: Implications for secondary prevention. Circulation 2000;101:2497-2502
16. Rajamannan NM, Subramaniam M, Rickard D, et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 2003;107:2181-2184
17. Mohler ER, III, Chawla MK, Chang AW, et al. Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis 1999;8:254-260
18. Yoshioka M, Yuasa S, Matsumura K, et al. Chondromodulin-I maintains cardiac valvular function by preventing angiogenesis. Nat Med 2006;12:1151-1159
19. Davis GE, Senger DR. Endothelial extracellular matrix: Biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 2005;97:1093-1107
20. Zijlstra A, Aimes RT, Zhu D, et al. Collagenolysis-dependent angiogenesis mediated by matrix metalloproteinase-13 (collagenase-3). J Biol Chem 2004;279:27633-27645
21. Mohler ER, III, Gannon F, Reynolds C, et al. Bone formation and inflammation in cardiac valves. Circulation 2001;103:1522-1528 (Pubitemid 32226259)
22. Poggianti E, Venneri L, Chubuchny V, Jambrik Z, Baroncini LA, Picano E. Aortic valve sclerosis is associated with systemic endothelial dysfunction. J Am Coll Cardiol 2003;41:136-141
23. Wallby L, Janerot-Sjöberg B, Steffensen T, Broqvist M. T lymphocyte infiltration in non-rheumatic aortic stenosis: A comparative descriptive study between tricuspid and bicuspid aortic valves. Heart 2002;88:348-351
24. Galante A, Pietroiusti A, Vellini M, et al. C-reactive protein is increased in patients with degenerative aortic valvular stenosis. J Am Coll Cardiol 2001;38:1078-1082
25. Ghaisas NK, Foley JB, O'Briain DS, et al. Adhesion molecules in nonrheumatic aortic valve disease: Endothelial expression, serum levels and effects of valve replacement. J Am Coll Cardiol 2000;36:2257-2262
26. Bergmeier C, Siekmeier R, Gross W. Distribution spectrum of paraoxonase activity in HDL fractions. Clin Chem 2004;50:2309-2315 (Pubitemid 39552166)
27. Tward A, Xia YR, Wang P, et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002;106:484-490
28. Yildiz A, Gur M, Yilmaz R, et al. Association of paraoxonase activity and coronary blood flow. Atherosclerosis 2008;197:257-263 (Pubitemid 351273247)
29. Gur M, Yildiz A, Demirbag R, et al. Paraoxonase and arylesterase activities in patients with cardiac syndrome X, and their relationship with oxidative stress markers. Coron Artery Dis 2007;18:89-95
30. Azarsiz E, Kayikcioglu M, Payzin S, Sözmen EY. PON1 activities and oxidative markers of LDL in patients with angiographically proven coronary artery disease. Int J Cardiol 2003;91:43-51 (Pubitemid 37101098)
31. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999;19:330-335
32. Mackness MI, Mackness B, Durrington PN, et al. Paraoxonase: Biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996;7:69-76
33. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol 1998;31:329-336
34. Navab M, Hama SY, Van Lanten BJ, et al. Mildly oxidized LDL induces an increased apolipoprotein/paraoxonase ratio. J Clin Invest 1997;99:2005-2019
35. Mackness M, Durrington P, Mackness B. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. Curr Opin Lipidol 2004;15:399-404 (Pubitemid 39061619)
36. Mackness M, Mackness B. Paraoxonase 1 and atherosclerosis: Is the gene or the protein more important? Free Radical Biol Med 2004;37:1317-1323